Pulmonary pharmacology / edited by W.S. Fred Wong.

Pulmonary Pharmacology, Volume 98 provides in-depth reviews on the latest progresses about respiratory drug discovery and development. Topics covered in this volume include corticosteroids, monoclonal antibodies, tyrosine kinase inhibitors and phosphodiesterase inhibitors for the treatments of asthm...

Full description

Saved in:
Bibliographic Details
Online Access: Full Text (via ScienceDirect)
Other Authors: Wong, W. S. Fred
Format: Electronic eBook
Language:English
Published: [Place of publication not identified] : Academic Press, 2023.
Series:Advances in pharmacology ; volume 98
Subjects:

MARC

LEADER 00000cam a22000007i 4500
001 in00000013297
006 m o d
007 cr |||||||||||
008 230803s2023 xx o 000 0 eng d
005 20230821201353.0
035 |a (OCoLC)scd1392092334 
037 |a scd10543589/98 
040 |a OPELS  |b eng  |e rda  |e pn  |c OPELS  |d EBLCP  |d YDX 
019 |a 1392341146 
020 |a 0443188815  |q (electronic bk.) 
020 |a 9780443188817  |q (electronic bk.) 
020 |z 9780443188800 
020 |z 0443188807 
029 1 |a AU@  |b 000074931368 
035 |a (OCoLC)1392092334  |z (OCoLC)1392341146 
050 4 |a RM388 
049 |a GWRE 
245 0 0 |a Pulmonary pharmacology /  |c edited by W.S. Fred Wong. 
264 1 |a [Place of publication not identified] :  |b Academic Press,  |c 2023. 
300 |a 1 online resource (312 pages) 
336 |a text  |b txt  |2 rdacontent 
337 |a computer  |b c  |2 rdamedia 
338 |a online resource  |b cr  |2 rdacarrier 
490 0 |a Advances in pharmacology ;  |v volume 98 
520 |a Pulmonary Pharmacology, Volume 98 provides in-depth reviews on the latest progresses about respiratory drug discovery and development. Topics covered in this volume include corticosteroids, monoclonal antibodies, tyrosine kinase inhibitors and phosphodiesterase inhibitors for the treatments of asthma, COPD or pulmonary fibrosis, with perspective on the development of novel therapeutic strategies such as renin-angiotensin system modulators, mitochondrial function modulators, and non-antibacterial macrolides. Part of the volume is devoted to senotherapy for lung ageing in respiratory diseases, and novel pulmonary delivery technologies, including inhaled biologics. 
588 0 |a Print version record. 
505 0 |a Intro -- Title page -- Table of Contents -- Advances in PHARMACOLOGY -- Copyright -- Contributors -- Preface -- Abbreviations -- Chapter One: Genomic and non-genomic effects of glucocorticoids in respiratory diseases -- Abstract -- Abbreviations -- 1 Introduction -- 2 Genomic mechanisms of action: GR activation -- 3 GR transactivation or transrepression-mediated mechanisms of action of GCs -- 4 Non-genomic mechanisms of action of GCs -- 5 Conclusion -- Acknowledgements -- References 
505 8 |a Chapter Two: Recent developments in the use of monoclonal antibodies targeting the type 2 cytokines for severe asthma treatment -- Abstract -- Abbreviation -- 1 Introduction -- 2 IL-5 -- 3 Mepolizumab -- 4 Reslizumab -- 5 Benralizumab -- 6 IL-4 and IL-13 -- 7 Dupilumab -- 8 Future developments -- 9 Conclusion -- Conflicts of interest -- References -- Chapter Three: Phosphodiesterase inhibitors and lung diseases -- Abstract -- Abbreviations -- 1 Introduction -- 2 Conclusion -- Conflict of interest statement -- References -- Chapter Four: Prospects for macrolide therapy of asthma and COPD 
505 8 |a Abstract -- Abbreviations -- 1 Introduction -- 2 Why asthma and COPD -- 3 What non-antimicrobial macrolide actions are relevant -- 4 Can antibiosis with macrolides be circumvented -- 5 Conclusion -- Acknowledgments -- References -- Note in proof -- Chapter Five: Targeting the renin angiotensin system for respiratory diseases -- Abstract -- Abbreviations -- 1 Introduction -- 2 Tareting renin angiotensin system in asthma -- 3 Targeting renin angiotensin system in COPD -- 4 Targeting renin angiotensin system in pulmonary fibrosis -- 5 Targeting renin angiotensin system in acute lung injury 
505 8 |a 6 Conclusion -- References -- Chapter Six: Progress in the development of kinase inhibitors for treating asthma and COPD -- Abstract -- Abbreviations -- 1 Introduction -- 2 Conclusion -- Conflict of interest statement -- References -- Chapter Seven: Anti-fibrotic strategies and pulmonary fibrosis -- Abstract -- Abbreviations -- 1 Introduction -- 2 IPF pathogenesis: Initiation of fibrogenesis -- 3 Pathways implicated in fibrosis -- 4 Growth factor and cytokine activation in IPF -- 5 Mechanotransduction and Hippo activation -- 6 Cellular players in IPF -- 7 IPF models -- 8 IPF drug treatment 
505 8 |a 9 Recommended drugs for IPF: Pirfenidone and nintedanib -- 10 Conclusion -- References -- Chapter Eight: Novel treatments against airway inflammation in COPD based on drug repurposing -- Abstract -- Abbreviations -- 1 Introduction -- 2 The novel pharmacologic targets -- 3 Conclusion -- Acknowledgements -- References -- Chapter Nine: Senotherapy for lung diseases -- Abstract -- Abbreviations -- 1 Introduction -- 2 Senotherapy for lung disease -- 3 Conclusion -- Conflict of interest -- References -- Chapter Ten: Delivery technology of inhaled therapy for asthma and COPD -- Abstract -- Abbreviations 
650 0 |a Pulmonary pharmacology. 
700 1 |a Wong, W. S. Fred. 
776 0 8 |i Print version:  |t PULMONARY PHARMACOLOGY.  |d [Place of publication not identified] : ELSEVIER ACADEMIC PRESS, 2023  |z 0443188807  |w (OCoLC)1365043066 
856 4 0 |u https://colorado.idm.oclc.org/login?url=https://www.sciencedirect.com/science/bookseries/10543589/98  |z Full Text (via ScienceDirect) 
915 |a 7 
956 |a ScienceDirect ebooks 
956 |b ScienceDirect All Books 
998 |b Added to collection elsevier.ebooks 
994 |a 92  |b COD 
999 f f |s 21cad091-a7e5-4585-937e-33a6f1f8a42d  |i 2156b5ff-6397-4950-9b77-73002ff994f2 
952 f f |p Can circulate  |a University of Colorado Boulder  |b Online  |c Online  |d Online  |h Library of Congress classification  |i web